Slide background

think antibodyomes!

MemoMAB™

 

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis (introductory video).

Its MemoMABTM platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

The business strategy of MEMO is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. MemoMABTM is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Learn more about antibodies, the human antibody library (discovery), immune repertoire analysis and antibody discovery deploying the huMemoMAB™ and rbMemoMAB™ platforms, respectively.

 

 

m

Discover the MemoMAB™ toolbox

Human immune repertoires

huMemo

 Antibody discovery from a human cognate antibody library.

>>

huMemo

 Immune repertoire analysis in humans for both healthy individuals and for patients.

>>

Animal immunization

rbMemo

Classical antibody discovery taking advantage of the superior rabbit immune response in combination with the highly efficient rbMemoMAB™ technology.

>>

 

m

Latest News

MEMO presented at Swiss Nordic Bio 2017 in Zurich

MEMO at conferences
MEMO presented in the investment stream at SNB 2017 in Zurich this year. Link to the conference …

Posted in 2017, News | Comments Off on MEMO presented at Swiss Nordic Bio 2017 in Zurich

First Client Project Completed – Validation of MemoMAB(TM) Platform

Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.
Basel/Zurich, …

Posted in 2016, News | Comments Off on First Client Project Completed – Validation of MemoMAB(TM) Platform

MEMO featured at ESMO conference in Lausanne, Switzerland

MEMO’s poster introducing the MemoMAB™ technology platform for the banking and screening of human immunoreceptor libraries was selected for the …

Posted in 2016, News | Comments Off on MEMO featured at ESMO conference in Lausanne, Switzerland

 

>>